Effects of adherence to ventilator-associated pneumonia treatment guidelines on clinical outcomes

Masahiro Sakaguchi, Nobuaki Shime, Naoya Iguchi, Atsuko Kobayashi, Koji Takada, Lee E. Morrow

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Two guidelines are currently available to guide Japanese clinicians caring for patients with ventilator-associated pneumonia (VAP): the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines or the 2008 Japanese Respiratory Society (JRS) guidelines. We aimed to measure compliance with guideline recommendations for VAP in Japanese intensive care units (ICUs) and to assess the effects of guideline-compliant treatment on outcomes. We retrospectively reviewed the records of all patients with microbiologically confirmed VAP in five Japanese ICUs between January 1, 2006, and December 31, 2009. We evaluated whether empiric antibiotic prescriptions were guideline compliant and correlated compliance with clinical outcomes. Among the 95 patients with VAP who were included, 85 patients received empiric antibiotics. Of these, therapy of 62 patients (73 %) was appropriate based on in vitro sensitivity testing. Using ATS/IDSA criteria, 16 patients (19 %) received guideline-compliant therapy and 69 patients (81 %) received noncompliant treatment. Using JRS criteria, 24 patients (28 %) received guideline-compliant therapy and 61 patients (72 %) received noncompliant treatment. All-cause 28-day mortality was 24 %. When compared to patients who received noncompliant therapy, there were no differences in 28-day mortality rates for patients who received ATS/IDSA guideline-compliant regimens (25 vs. 25 %, p = 1.00) or JRS guideline-compliant regimens (21 vs. 26 %, p = 0.78). Our study demonstrates poor compliance with guideline-recommended antibiotic therapy for VAP in Japanese ICUs. Compliance with current VAP guidelines was not associated with increased rates of appropriate antibiotic treatment or improved 28-day mortality.

Original languageEnglish
Pages (from-to)599-606
Number of pages8
JournalJournal of Infection and Chemotherapy
Volume19
Issue number4
DOIs
StatePublished - Aug 2013

Fingerprint

Ventilator-Associated Pneumonia
Guidelines
Therapeutics
Anti-Bacterial Agents
Intensive Care Units
Communicable Diseases
Mortality
Thorax
Prescriptions

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Effects of adherence to ventilator-associated pneumonia treatment guidelines on clinical outcomes. / Sakaguchi, Masahiro; Shime, Nobuaki; Iguchi, Naoya; Kobayashi, Atsuko; Takada, Koji; Morrow, Lee E.

In: Journal of Infection and Chemotherapy, Vol. 19, No. 4, 08.2013, p. 599-606.

Research output: Contribution to journalArticle

Sakaguchi, Masahiro ; Shime, Nobuaki ; Iguchi, Naoya ; Kobayashi, Atsuko ; Takada, Koji ; Morrow, Lee E. / Effects of adherence to ventilator-associated pneumonia treatment guidelines on clinical outcomes. In: Journal of Infection and Chemotherapy. 2013 ; Vol. 19, No. 4. pp. 599-606.
@article{fa46a37670624e1fb3f4c272bea7b66c,
title = "Effects of adherence to ventilator-associated pneumonia treatment guidelines on clinical outcomes",
abstract = "Two guidelines are currently available to guide Japanese clinicians caring for patients with ventilator-associated pneumonia (VAP): the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines or the 2008 Japanese Respiratory Society (JRS) guidelines. We aimed to measure compliance with guideline recommendations for VAP in Japanese intensive care units (ICUs) and to assess the effects of guideline-compliant treatment on outcomes. We retrospectively reviewed the records of all patients with microbiologically confirmed VAP in five Japanese ICUs between January 1, 2006, and December 31, 2009. We evaluated whether empiric antibiotic prescriptions were guideline compliant and correlated compliance with clinical outcomes. Among the 95 patients with VAP who were included, 85 patients received empiric antibiotics. Of these, therapy of 62 patients (73 {\%}) was appropriate based on in vitro sensitivity testing. Using ATS/IDSA criteria, 16 patients (19 {\%}) received guideline-compliant therapy and 69 patients (81 {\%}) received noncompliant treatment. Using JRS criteria, 24 patients (28 {\%}) received guideline-compliant therapy and 61 patients (72 {\%}) received noncompliant treatment. All-cause 28-day mortality was 24 {\%}. When compared to patients who received noncompliant therapy, there were no differences in 28-day mortality rates for patients who received ATS/IDSA guideline-compliant regimens (25 vs. 25 {\%}, p = 1.00) or JRS guideline-compliant regimens (21 vs. 26 {\%}, p = 0.78). Our study demonstrates poor compliance with guideline-recommended antibiotic therapy for VAP in Japanese ICUs. Compliance with current VAP guidelines was not associated with increased rates of appropriate antibiotic treatment or improved 28-day mortality.",
author = "Masahiro Sakaguchi and Nobuaki Shime and Naoya Iguchi and Atsuko Kobayashi and Koji Takada and Morrow, {Lee E.}",
year = "2013",
month = "8",
doi = "10.1007/s10156-012-0522-4",
language = "English",
volume = "19",
pages = "599--606",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Effects of adherence to ventilator-associated pneumonia treatment guidelines on clinical outcomes

AU - Sakaguchi, Masahiro

AU - Shime, Nobuaki

AU - Iguchi, Naoya

AU - Kobayashi, Atsuko

AU - Takada, Koji

AU - Morrow, Lee E.

PY - 2013/8

Y1 - 2013/8

N2 - Two guidelines are currently available to guide Japanese clinicians caring for patients with ventilator-associated pneumonia (VAP): the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines or the 2008 Japanese Respiratory Society (JRS) guidelines. We aimed to measure compliance with guideline recommendations for VAP in Japanese intensive care units (ICUs) and to assess the effects of guideline-compliant treatment on outcomes. We retrospectively reviewed the records of all patients with microbiologically confirmed VAP in five Japanese ICUs between January 1, 2006, and December 31, 2009. We evaluated whether empiric antibiotic prescriptions were guideline compliant and correlated compliance with clinical outcomes. Among the 95 patients with VAP who were included, 85 patients received empiric antibiotics. Of these, therapy of 62 patients (73 %) was appropriate based on in vitro sensitivity testing. Using ATS/IDSA criteria, 16 patients (19 %) received guideline-compliant therapy and 69 patients (81 %) received noncompliant treatment. Using JRS criteria, 24 patients (28 %) received guideline-compliant therapy and 61 patients (72 %) received noncompliant treatment. All-cause 28-day mortality was 24 %. When compared to patients who received noncompliant therapy, there were no differences in 28-day mortality rates for patients who received ATS/IDSA guideline-compliant regimens (25 vs. 25 %, p = 1.00) or JRS guideline-compliant regimens (21 vs. 26 %, p = 0.78). Our study demonstrates poor compliance with guideline-recommended antibiotic therapy for VAP in Japanese ICUs. Compliance with current VAP guidelines was not associated with increased rates of appropriate antibiotic treatment or improved 28-day mortality.

AB - Two guidelines are currently available to guide Japanese clinicians caring for patients with ventilator-associated pneumonia (VAP): the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines or the 2008 Japanese Respiratory Society (JRS) guidelines. We aimed to measure compliance with guideline recommendations for VAP in Japanese intensive care units (ICUs) and to assess the effects of guideline-compliant treatment on outcomes. We retrospectively reviewed the records of all patients with microbiologically confirmed VAP in five Japanese ICUs between January 1, 2006, and December 31, 2009. We evaluated whether empiric antibiotic prescriptions were guideline compliant and correlated compliance with clinical outcomes. Among the 95 patients with VAP who were included, 85 patients received empiric antibiotics. Of these, therapy of 62 patients (73 %) was appropriate based on in vitro sensitivity testing. Using ATS/IDSA criteria, 16 patients (19 %) received guideline-compliant therapy and 69 patients (81 %) received noncompliant treatment. Using JRS criteria, 24 patients (28 %) received guideline-compliant therapy and 61 patients (72 %) received noncompliant treatment. All-cause 28-day mortality was 24 %. When compared to patients who received noncompliant therapy, there were no differences in 28-day mortality rates for patients who received ATS/IDSA guideline-compliant regimens (25 vs. 25 %, p = 1.00) or JRS guideline-compliant regimens (21 vs. 26 %, p = 0.78). Our study demonstrates poor compliance with guideline-recommended antibiotic therapy for VAP in Japanese ICUs. Compliance with current VAP guidelines was not associated with increased rates of appropriate antibiotic treatment or improved 28-day mortality.

UR - http://www.scopus.com/inward/record.url?scp=84882249859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882249859&partnerID=8YFLogxK

U2 - 10.1007/s10156-012-0522-4

DO - 10.1007/s10156-012-0522-4

M3 - Article

VL - 19

SP - 599

EP - 606

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 4

ER -